Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT01020539 Completed - Clinical trials for Myelodysplastic Syndrome

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

AML/MDS/JMML
Start date: September 11, 2002
Phase: Phase 1
Study type: Interventional

Allogeneic stem cell transplantation (AlloSCT) followed by targeted immune therapy Gemtuzumab Ozogamicin patients with acute myeloid leukemia (AML)/juvenile myelomonocytic leukemia (JMML)/myelodysplastic syndromes (MDS) will be safe and well tolerated.

NCT ID: NCT01020175 Completed - Clinical trials for Myelodysplastic Syndrome

Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation

Start date: January 1995
Phase: Phase 3
Study type: Interventional

350 patients with early leukemias were assigned to receive peripheral blood or bone marrow transplantation; the occurrence of acute and chronic graft versus host disease, survival, transplantation-related mortality, and relapse rates were compared.

NCT ID: NCT01019317 Completed - Leukemia Clinical Trials

Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Start date: November 2009
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if the combination of fludarabine and cytarabine can help to control Acute Myelogenous Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myeloid Leukemia (CML) in myeloid blast crisis. The safety of this drug combination will also be studied.

NCT ID: NCT01019161 Completed - Clinical trials for Acute Myeloid Leukaemia

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

Start date: November 2009
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess how AZD1152 is absorbed or excreted in and out of the body in patients with Acute Myeloid Leukaemia (AML).

NCT ID: NCT01018069 Terminated - Leukemia Clinical Trials

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Start date: November 2009
Phase: Phase 2
Study type: Interventional

To determine if AEG35156 can enhance the combined complete remission (CR) and CR with incomplete platelet recovery (CRp) rate of high-dose cytarabine and idarubicin in AML following failure of a single standard dose cytarabine based frontline induction regimen.

NCT ID: NCT01016990 Recruiting - Lymphoma Clinical Trials

Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia

Start date: August 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Valproic acid may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It may also help cancer cells become more like normal cells, and grow and spread more slowly. PURPOSE: This phase II trial is studying how well valproic acid works in treating patients with previously treated non-Hodgkin Lymphoma, Hodgkin lymphoma, or chronic lymphocytic leukemia.

NCT ID: NCT01016600 Completed - Clinical trials for Leukemia, Myeloid, Acute

Azacitidine and Lenalidomide for Acute Myeloid Leukemia

Start date: April 2010
Phase: Phase 1/Phase 2
Study type: Interventional

Determine toxicity and remission rates of treatment with azacitidine and lenalidomide for patients with Acute Myeloid Leukemia

NCT ID: NCT01016379 Completed - Leukemia Clinical Trials

Studying DNA in Blood and Bone Marrow Samples From Young Patients With Acute Lymphoblastic Leukemia

Start date: November 2009
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is looking at DNA in blood and bone marrow samples from young patients with acute lymphoblastic leukemia.

NCT ID: NCT01015742 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

Unrelated Double Umbilical Cord Blood Units Transplantation

Start date: November 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and feasibility of unrelated double umbilical cord blood units Transplantation in patients with haematological malignancies using Antithymocyte Globulin Cyclophosphamide, busulfan as conditioning and cyclosporin, methylprednisolone as GVHD prophylaxis.

NCT ID: NCT01014195 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors

Start date: January 2010
Phase: N/A
Study type: Observational

1. This study will evaluate the association between changes in basic cognitive and behavioral functioning by the end of chemotherapy treatment, and the later development of higher order executive functions in pediatric acute lymphoblastic leukemia (ALL). 2. The association between acute treatment-related changes in brain integrity and subsequent brain maturation in long-term survivors of pediatric ALL will be evaluated. 3. The association between patterns of behavioral and executive dysfunction and brain maturation in long-term survivors of pediatric ALL will be examined. 4. The association between genetic polymorphisms in key enzyme pathways and higher order brain development in long-term survivors of pediatric ALL will be explored. 5. The associations between biologic and behavioral indices of fatigue/sleep and higher order brain development in long-term survivors of pediatric ALL will be explored.